Accessory Sex Glands in the Male

Knobil and Neill's Physiology of Reproduction: Two-Volume Set

Volumn 1, Issue , 2015, Pages 773-804

  Prins, Gail S ^a   Lindgren, Mark ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Accessory; Androgen; Bulbourethral; Plasma; Prostate; Semen; Seminal vesicle; Sex gland

Indexed keywords

EID: 84942853268     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397175-3.00018-1     Document Type: Chapter

References (310)

1. Coffey D.S. Androgen action and the sex accessory tissues. The physiology of reproduction 1988, 1081-1120. Raven Press, New York. E. Knobil, J.D. Neill, L.L. Ewing, G.S. Greenwald, C.L. Markert, D.W. Pfaff (Eds.).
2. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, based on November 2011 SEER data submission [accessed 04.01.2012]. http://seer.cancer.gov/csr/1975_2009_pops09/.
3. Berry S., Coffey D., Walsh P., Ewing L. The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474-479.
4. Clemens J.Q., Meenan R.T., O'Keeffe-Rosetti M.C., Gao S.Y., Brown S.O., Calhoun E.A. Prevalence of prostatitis-like symptoms in a managed care population. J Urol 2006, 176:593-596. discussion 6.
5. Nickel J.C., Teichman J.M., Gregoire M., Clark J., Downey J. Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE Study. Urology 2005, 66:935-940.
6. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest Urol 1978, 15:340-345.
7. Lawson R.K. A historical view of prostate disease. Prostate diseases 1993, W.B. Saunders, Philadelphia. H. Lepor, R.K. Lawson (Eds.).
8. Riolan J. Opera anatomica: vertera, recognita, et auctiora, quam-plurima nova 1649, Sumptibus G. Meturas, Lutetiae Parisiorum (Paris).
9. Morgagni G.B., Alexander B., Klemperer P. The seats and causes of diseases, investigated by anatomy: in five books, containing a great variety of dissections, with remarks 1960, To which are added very accurate and copious indexes of the principal things and names therein contained. (Venice, 1761). [English Trans. 1796], Futura Publishing Co., Mt Kisco, NY.
10. Hunter J. A treatise on the venereal disease 1788, 2nd edition., G Nicol and J Johnson, London.
11. Overall G.W. A non-surgical treatise on diseases of the prostate gland and adnexa 1903, Marsh and Grant Co., Chicago.
12. Huggins C., Hodges C.F. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
13. Fang S., Anderson K.M., Liao S. Receptor proteins for androgens. J Biochem 1969, 244:6584-6595.
14. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326.
15. Cunha G.R. Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin. Anat Rec 1972, 172:529-541.
16. McNeal J.E. The prostate gland: morphology and pathobiology. Monogr Urol 1983, 4:3-11.
17. Chung B.I., Sommer G., Brooks J.D. Anatomy of the lower urinary tract and male genitalia. Campbell-walsh Urology 2011, 33-70. Elsevier Saunders, Philadelphia. 10th ed. A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters (Eds.).
18. Price D., Williams-Ashman H.G. The accessory reproductive glands of mammals 1961, Williams & Wilkens Co., Baltimore. 3rd ed.
19. Price D. Comparative aspects of development and structure in the prostate. Biology of the prostate and related tissues 1963, 1-27. National Cancer Institute, Washington, DC. E.P. Vollmer (Ed.).
20. Hayashi N., Sugimura Y., Kawamura J., Donjacour A.A., Cunha G.R. Morphological and functional heterogeneity in the rat prostatic gland. Biol Reprod 1991, 45:308-321.
21. Jesik C., Holland J., Lee C. An anatomic and histologic study of the rat prostate. Prostate 1982, 3:81-97.
22. Huang L., Pu Y., Birch L., Prins G.S. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007, 148:1235-1245.
23. Xu J., Lange E.M., Lu L., et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2012, October 12, Epub ahead of print.
24. McNeal J.E. Anatomy and normal histology of the human prostate. Pathology of the Prostate 1998, 19-34. W.B. Saunders Co., Philadelphia. C.S. Foster, D.G. Bostwick (Eds.).
25. Forest M.G. Plasma androgens (testosterone and 4-androstenedione) and 17-hydroxyprogesterone in the neonatal, prepubertal and peripubertal periods in the human and the rat: differences between species. J Steroid Biochem 1979, 11:543-548.
26. El-Alfy M., Pelletier G., Hermo L.S., Labrie F. Unique features of the basal cells of human prostate epithelium. Microsc Res Tech 2000, 51:436-446.
27. di Sant'Agnese P.A., Cockett A.T. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996, 78:357-361.
28. Wang Y., Hayward S.W., Cao M., Thayer K., Cunha G.R. Cell differentiation lineage in the prostate. Differentiation 2001, 68:270-279.
29. Sherwood E., Theyer G., Steiner G., Berg L., Kozlowski J., Lee C. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate 1991, 18:303-314.
30. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., et al. Roles for Nkx3.1 in prostate development and cancer. Gend Dev 1999, 13:966-977.
31. Bonkhoff H., Remberer K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996, 28:98-106.
32. Epstein J.I. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 1993, 20:757-770.
33. Bonkhoff H., Wernert N., Dhom G., Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991, 19:91-98.
34. Abrahamsson P.A., Dizeyi N., Alm P., di Sant'Agnese P.A., Deftos L.J., Aumuller G. Calcitonin and calcitonin gene-related peptide in the human prostate gland. Prostate 2000, 44:181-186.
35. Fujimoto N., Suzuki T., Ohta S., Kitamura S. Identification of rat prostatic secreted proteins using mass spectrometric analysis and androgen-dependent mRNA expression. J Androl 2009, 30:669-678.
36. Prins G.S., Woodham C., Lepinske M., Birch L. Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 1993, 132:2387-2398.
37. Wright A.S., Thomas L.N., Douglas R.C., Lazier C.B., Rittmaster R.S. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996, 98:2558-2563.
38. Prins G.S., Birch L., Greene G.L. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991, 129:3187-3199.
39. Habermann H., Chang W.Y., Birch L., Mehta P., Prins G.S. Developmental exposure to estrogens alters epithelial cell adhesion and gap junction proteins in the adult rat prostate. Endocrinology 2001, 142:359-369.
40. Cohen R.J., Glezerson G., Taylor L.F., Grundle H.A., Naude J.H. The neuroendocrine cell population of the human prostate gland. J Urol 1993, 150:365-368.
41. Nemeth J., Sensibar J., White R., Zelner D., Kim I., Lee C. Prostatic ductal system in rats: tissue-specific expression and regional variation in stromal distribution of transforming growth factorβ1. Prostate 1997, 33:64-71.
42. Hayward S., Baskin L., Haughney P., et al. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. Acta Anat (Basel) 1996, 155:94-103.
43. Cunha G.R., Donjacour A.A., Cooke P.S., et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987, 8:338-363.
44. Prins G.S., Cooke P.S., Birch L., et al. Androgen receptor expression and 5α-reductase activity along the proximal-distal axis of the rat prostatic duct. Endocrinology 1992, 130:3066-3073.
45. Cunha G.R., Hayward S.W., Dahiya R., Foster B.A. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) 1996, 155:63-72.
46. Redman J.F. Anatomy of the genitourinary system. Adult and pediatric urology 1987, 3-62. Mosby-Year Book, St. Louis. 2nd ed. J.Y. Gillenwater, J.T. Grahack, S.S. Howards, J.W. Duckett (Eds.).
47. Laczko I., Hudson D.L., Freeman A., Feneley M.R., Masters J.R. Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. Prostate 2005, 62:260-266.
48. Chughtai B., Sawas A., O'Malley R.L., Naik R.R., Ali Khan S., Pentyala S. A neglected gland: a review of Cowper's gland. Int J Androl 2005, 28:74-77.
49. Parr M.B., Ren H.P., Russell L.D., Prins G.S., Parr E.L. Urethral glands of the male mouse contain secretory component and immunoglobulin A plasma cells and are targets of testosterone. Biol Reprod 1992, 47:1031-1039.
50. Prins G.S., Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008, 76:641-659.
51. Lowsley O.S. The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. Am J Anat 1912, 13:299-348.
52. Shapiro E. Embryologic development of the prostate. Urol Clin North Am 1990, 17:487-493.
53. Prins G.S. Development of the prostate. Reproductive issues and the aging male 1993, 101-112. Embryonic, Inc., New York. F. Haseltine, C. Paulsen, C. Wang (Eds.).
54. Kellokumpu-Lehtinen P. Development of sexual dimorphism in human urogenital sinus complex. Biol Neonate 1985, 48:157-167.
55. Jirasek J.E. Normal development of the male accessory glands. Male accessory sex glands 1980, 3-37. Elsevier/North-Holland Biomedical Press, New York. E. Spring-Mills, E.S.E. Hafez (Eds.).
56. Zondek T., Zondek L.H. The fetal and neonatal prostate. Normal and abnormal growth of the prostate 1975, 5-28. Thomas C. Thomas, Springfield, IL. M. Goland (Ed.).
57. De Klerk D.P., Lombard C.J. Stromal and epithelial growth of the prostate during puberty. Prostate 1986, 9:191-198.
58. Sugimura Y., Cunha G.R., Donjacour A.A. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 1986, 34:961-971.
59. Timms B.G., Mohs T.J., Didio L.J. Ductal budding and branching patterns in the developing prostate. J Urol 1994, 151:1427-1432.
60. Prins G.S., Birch L. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 1995, 136:1303-1314.
61. Hayward S.W., Baskin L.S., Haughney P.C., et al. Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) 1996, 155:81-93.
62. Chang W.Y., Wilson M.J., Birch L., Prins G.S. Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. Endocrinology 1999, 140:405-415.
63. Shabsigh A., Tanji N., D'Agati V., et al. Vascular anatomy of the rat ventral prostate. Anat Rec 1999, 256:403-411.
64. Xin L., Lukacs R.U., Lawson D.A., Cheng D., Witte O.N. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 2007, 25:2760-2769.
65. Leong K.G., Wang B.E., Johnson L., Gao W.Q. Generation of a prostate from a single cell. Nature 2008, 456:804-808.
66. Goldstein A.S., Lawson D.A., Cheng D., Sun W., Garraway I.P., Witte O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008, 105:20882-20887.
67. Vander Griend D.J., Karthaus W.L., Dalrymple S., Meeker A., DeMarzo A.M., Isaacs J.T. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008, 68:9703-9711.
68. Morrison S.J., Kimble J. Asymmetric and symmetric stem cell divisions in development and cancer. Nature 2006, 441:1068-1074.
69. Scaffidi P., Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011, 19:1051-1056.
70. Wu C.T., Altuwaijri S.R.W., Huang S.P., et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007, 104:12679-12684.
71. Tomasetti C., Levy D. Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci USA 2010, 107:16766-16771.
72. Tsujimura A., Koikawa Y., Salm S., et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002, 157:1257-1265.
73. Goto K., Salm S.N., Coetzee S., et al. Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells 2006, 24:1859-1868.
74. Hudson D.L. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 2004, 7:188-194.
75. Isaacs J.T. Prostate stem cells and benign prostatic hyperplasia. Prostate 2008, 68:1025-1034.
76. Kasper S. Characterizing the prostate stem cell. J Urol 2007, 178:375.
77. Wang Y., Chang W.Y., Prins G.S., van Breeman R.B. Simultaneous determination of all-trans, 9-cis, 13-cis retinoic acid and retinal in rat prostate using liquid. J Mass Spectrom 2001, 36:882-888.
78. Long R.M., Morrissey C., Fitzpatrick J.M., Watson R.W. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci 2005, 108:1-11.
79. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate 1982, (Suppl. 2):33-50.
80. Hudson D.L., O'Hare M., Watt F.M., Masters J.R. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2000, 80:1243-1250.
81. Garraway L.A., Lin D., Signoretti S., et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003, 55:206-218.
82. Blum R., Gupta R., Burger P.E., et al. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. PLoS One 2010, 5:1-214.
83. Kasper S. Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol 2009, 27:301-303.
84. Hu W.Y., Shi G.B., Hu D.P., Nelles J.L., Prins G.S. Actions of endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol 2012, 354:63-73.
85. Berry P.A., Maitland N.J., Collins A. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol 2008, 288:30-37.
86. Hu W.Y., Shi G.B., Lam H.M., et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 2011, 152:2150-2163.
87. Tanagho E.A., Nguyen H.T. Embryology of the genitourinary system. Smith's general urology 2008, 17-29. McGraw-Hill. 17th ed. E.A. Tanagho, J.W. McAninch (Eds.).
88. Price D. Normal development of the prostate and seminal vesicles of the rat with a study of experimental postnatal modifications. Am J Anat 1936, 60:79-127.
89. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Rec Prog Horm Res 1953, 8:379-418.
90. Cunha G.R. The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 1973, 175:87-96.
91. Lasnitzki I., Mizuno T. Induction of the rat prostate gland by androgens in organ culture. J Endocrinol 1977, 74:47-55.
92. Lipschutz J., Foster B., Cunha G. Differentiation of rat neonatal ventral prostates grown in a serum-free organ culture system. Prostate 1997, 32:35-42.
93. Allgeier S.H., Lin T.M., Moore R.W., Vezina C.M., Abler L.L., Peterson R.E. Androgenic regulation of ventral epithelial bud number and pattern in mouse urogenital sinus. Dev Dyn 2010, 239:373-385.
94. Wilson J., Gloyna R. The intranuclear metabolism of testosterone in the accessory organs of reproduction. Rec Prog Horm Res 1970, 26:309-336.
95. Sitteri P.K., Wilson J.D. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab 1974, 38:113-125.
96. Wilson J.D., Lasnitzki I. Dihydrotestsoterone formation in the fetal tissue of the rabbit and rat. Endocrinology 1971, 89:659.
97. Rajfer J., Coffey D.S. Sex steroid imprinting of the immature prostate. Invest Urol 1978, 16:186-190.
98. Nuclear Receptors Nomenclature Committee A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97:161-163.
99. Brown T.R. Human androgen insensitivity syndrome. J Androl 1995, 16:299-303.
100. Cunha G.R., Shannon J.M., Vanderslice K.D., McCormick K., Bigsby R.M. Autoradiographic demonstration of high affinity nuclear binding and finite binding capacity of 3H-estradiol in mouse vaginal cells. Endocrinology 1983, 113:1427-1430.
101. Cunha G.R., Chung L.W. Stromal-epithelial interactions: I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/Y) mice. J Steroid Biochem 1981, 14:1317-1321.
102. Donjacour A.A., Cunha G.R. Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice. Endocrinology 1993, 132:2342-2350.
103. Cunha G.R. Mesenchymal-epithelial interactions: past, present, and future. Differentiation 2008, 76:578-586.
104. Cunha G.R., Battle E., Young P., et al. Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol 1992, 1:76-83.
105. Simanainen U., Allan C.M., Lim P., et al. Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 2007, 148:2264-2272.
106. Prins G.S., Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 1997, 138:1801-1809.
107. Prins G.S., Marmer M., Woodham C., et al. Estrogen receptorβ messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998, 139:874-883.
108. Prins G.S., Birch L., Habermann H., et al. Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev 2001, 13:241-252.
109. vom Saal F.S., Timms B.G., Montano M.M., et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997, 94:2056-2061.
110. Prins G.S., Birch L., Couse J.F., Choi I., Katzenellenbogen B., Korach K.S. Estrogen imprinting of the developing prostate gland in mediated through stromal estrogen receptor α: studies with αERKO and βERKO mice. Cancer Res 2001, 61:6089-6097.
111. Huang L., Pu Y., Alam S., Birch L., Prins G.S. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl 2004, 25:330-337.
112. Prins G.S., Huang L., Birch L., Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 2006, 1089:1-13.
113. Huang L., Pu Y., Hu W.Y., et al. The role of Wnt5a in prostate gland development. Dev Biol 2009, 328:188-199.
114. Prins G.S., Tang W.Y., Belmonte J., Ho S.M. Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 2008, 102:134-138.
115. Prins G.S., Ho S.M. Early life estrogens and prostate cancer in an animal model. J Dev Orig Health Dis 2010, 365-370. online November 9, 2010.
116. Ekbom A., Wuu J., Adami H.O., et al. Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol Biomarkers Prev 2000, 9:221-223.
117. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994, 5:115-125.
118. Prins G.S., Chang W.Y., Wang Y., van Breemen R.B. Retinoic acid receptors and retinoids are up-regulated in the developing and adult rat prostate by neonatal estrogen exposure. Endocrinology 2002, 143:3628-3640.
119. Vezina C.M., Allgeier S.H., Fritz W.A., et al. Retinoic acid induces prostatic bud formation. Dev Dyn 2008, 237:1321-1333.
120. Witte L.P., Chapple C.R., de la Rosette J.J., Michel M.C. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 2008, 54:326-334.
121. McVary K.T., McKenna K.E., Lee C. Prostate innervation. Prostate Suppl 1998, 8:2-13.
122. Hogan B.L.M. Morphogenesis. Cell 1999, 96:225-233.
123. Gehring W. The discovery of the homeobox. Guidebook to the homeobox genes 1994, 3-10. Oxford University Press, New York. D. Duboule (Ed.).
124. Krumlauf R. Hox genes in vertebrate development. Cell 1994, 78:191-201.
125. Podlasek C.A., Duboule D., Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn 1997, 208:454-465.
126. Podlasek C.A., Clemens J.Q., Bushman W. Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. J Urol 1999, 161:1655-1661.
127. Warot X., Fromental-Ramain C., Fraulob V., Chambon P., Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 1997, 124:4781-4791.
128. Oefelein M., Chin-Chance C., Bushman W. Expression of the homeotic gene Hox-d13 in the developing and adult mouse prostate. J Urol 1996, 155:342-346.
129. Sreenath T., Orosz A., Fujita K., Bieberich C.J. Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 1999, 41:203-207.
130. Economides K.D., Capecchi M.R. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 2003, 130:2061-2069.
131. Xu J., Lange E.M., Lu L., et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2012.
132. Ewing C.M., Ray A.M., Lange E.M., et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012, 366:141-149.
133. Moens C.B., Selleri L. Hox cofactors in vertebrate development. Dev Biol 2006, 291:193-206.
134. Chen J.L., Li J., Kiriluk K.J., et al. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res 2012, 18:4291-4302.
135. Bieberich C.J., Fujita K., He W.W., Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 1996, 271:31779-31782.
136. Schiavolino P.J., Abrams E.W., Yang L., Austenberg L.P., Shen M.M., Abate-Shen C. Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev Dyn 1997, 209:127-138.
137. Brennan K.R., Brown A.M.C. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004, 9:119-131.
138. Abate-Shen C., Shen M.M., Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008, 76:717-727.
139. Prescott J., Blok L., Tindall D. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 1998, 35:71-80.
140. Pu Y., Huang L., Birch L., Prins G.S. Androgen regulation of prostate morphoregulatory gene expression: Fgf10-dependent and -independent pathways. Endocrinology 2007, 148:1697-1706.
141. Schneider A., Brand T., Zweigerdt R., Arnold H. Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mech Dev 2000, 95:163-174.
142. Kaestner K.H., Knochel W., Martinez D.E. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000, 14:142-146.
143. Clevidence D.E., Overdier D.G., Tao W., et al. Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. Proc Natl Acad Sci USA 1993, 90:3948-3952.
144. Mirosevich J., Gao N., Matusik R.J. Expression of Foxa transcription factors in the developing an adult murine prostate. Prostate 2004, 62:339-352.
145. Kopachik W., Hayward S.W., Cunha G.R. Expression of hepatocyte nuclear factor-3α in rat prostate, seminal vesicle, and bladder. Dev Dyn 1998, 211:131-140.
146. Gao N., Ishii K., Mirosevich J., et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005, 132:4331-4343.
147. Zhang C., Wang L., Wu D., et al. Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res 2011, 71:6738-6748.
148. Thomsen M.K., Butler C.M., Shen M.M., Swain A. Sox9 is required for prostate development. Dev Biol 2008, 316:302-311.
149. Huang Z., Hurley P.J., Simons B.W., et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012, 3:651-663.
150. Wang H., Leav I., Ibaragi S., et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 2008, 68:1625-1630.
151. Wang H., McKnight N.C., Zhang T., Lu M.L., Balk S.P., Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 2007, 67:528-536.
152. Bolos V., Grego-Bessa J., de la Pompa J.L. Notch signaling in development and cancer. Endocr Rev 2007, 28:339-363.
153. Grishina I.B., Kinm S.Y., Ferrara C., Makarenkova H.P., Walden P.D. BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling. Dev Biol 2005, 288:334-347.
154. Shou J., Ross S., Koeppen H., de Sauvage F.J., Gao W.Q. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001, 61:7291-7297.
155. Wu X., Xu K., Zhang L., et al. Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol 2011, 356:337-349.
156. Wang X.D., Shou J., Wong P., French D.M., Gao W.Q. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 2004, 279:24733-24744.
157. Valdez J.M., Zhang L., Su Q., et al. Notch and TGFbeta form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell 2012, 11:676-688.
158. Ingham P.W., McMahon A.P. Review: hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001, 15:3059-3087.
159. Gritli-Linde A., Lewis P., McMahon A.P., Linde A. The whereabouts of a morphogen: direct evidence for short-and graded long-range activity of hedgehog signaling peptides. Dev Biol 2001, 236:364-386.
160. Podlasek C.A., Barnett D.H., Clemens J.Q., Bak P.M., Bushman W. Prostate development requires sonic hedgehog expressed by the urogenital sinus epithelium. Dev Biol 1999, 209:28-39.
161. Lamm M.L., Catbagan W.S., Laciak R.J., et al. Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. Dev Biol 2002, 249:349-366.
162. Berman D.M., Desai N., Wang X., et al. Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. Devel Biol 2004, 267:387-398.
163. Pu Y., Huang L., Prins G.S. Sonic hedgehog-patched-gli signaling in the developing rat prostate gland: lobe-specific suppression by neonatal estrogens reduces ductal growth and branching. Dev Biol 2004, 273:257-275.
164. Barnett D.H., Huang H.Y., Wu X.R., Laciak R., Shapiro E., Bushman W. The human prostate expresses sonic hedgehog during fetal development. J Urol 2002, 168:2206-2210.
165. Zhu G., Zhau H.E., He H., et al. Sonic and desert hedgehog signaling in human fetal prostate development. Prostate 2007, 67:674-684.
166. Freestone S.H., Marker P., Grace O.C., et al. Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol 2003, 264:352-362.
167. Shaw A., Bushman W. Hedgehog signaling in the prostate. J Urol 2007, 177:832-838.
168. Tzelepi V., Karlou M., Wen S., et al. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 2011, 58:1037-1047.
169. Shigemura K., Huang W.C., Li X., et al. Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate 2011, 71:1711-1722.
170. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol 2001, 2:1-12.
171. Raman R., Venkataraman G., Ernst S., Sasisekharan V., Sasisekharan R. Structural specificty of heparin binding growth factor family of proteins. Proc Natl Acad Sci USA 2003, 100:2357-2362.
172. Uematsu F., Kan M., Wang F., Jang J.H., Luo Y., McKeehan W.L. Ligand binding properties of binary complexes of heparin and immunoglobulin-like modules of FGF receptor 2. Biochem Biopjys Res Commun 2000, 272:830-836.
173. Bellusci S., Grindley J., Emoto H., Itoh N., Hogan B. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 1997, 124:4867-4878.
174. Thomson A.A., Cunha G.R. Prostatic growth and development are regulated by FGF10. Development 1999, 126:3693-3701.
175. Huang L., Pu Y., Alam S., Birch L., Prins G.S. The role of Fgf10 signaling in branching morphogenesis and gene expression in the rat prostate gland: lobe-specific supression by neonatal estrogens. Dev Biol 2005, 278:396-414.
176. Donjacour A.A., Thomson A.A., Cunha G. FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol 2003, 261:39-54.
177. Lin Y., Liu G., Zhang Y., et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 2007, 134:723-734.
178. Lu W., Luo Y., Kan M., McKeehan W.L. Fibroblast growth factor-10: a second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999, 274:12827-12834.
179. Hogan B.L.M. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996, 6:432-438.
180. Lamm M.L., Podlasek C.A., Barnett D.H., et al. Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol 2001, 232:301-314.
181. Cook C., Vezina C.M., Allgeier S.H., et al. Noggin is required for normal lobe patterning and ductal budding in the mouse prostate. Dev Biol 2007, 312:217-230.
182. cip1/wafl expression associated with epithelial differentiation. Endocrinology 1999, 140:2801-2813.
183. Itoh N., Patel U., Cupp A., Skinner M. Developmental and hormonal regulation of transforming growth factorβ1 (TGF β1), -2, and -3 gene expression in isolated prostatic epithelial and stromal cells: epidermal growth factor and TGFβ interactions. Endocrinology 1998, 139:1378-1388.
184. Tomlinson D.C., Gindley J.C., Thomson A.A. Regulation of Fgf10 gene expression in the Prostate: Identification of transforming growth factorß1 and promoter elements. Endocrinology 2004, 145:1988-1995.
185. Tomlinson D.C., Freestone S.H., Grace O.C., Thomson A.A. Differential effects of transforming growth factorβ1 on cellular proliferation in the developing prostate. Endocrinology 2004, 145:4292-4300.
186. Gerdes M., Dang T., Larsen M., Rowley D. Transforming growth factorβ1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle ells. Endocrinology 1998, 139:3569-3577.
187. Cancilla B., Jarred R.A., Wang H., Mellow S.L., Cunha G.R., Risbridger G.P. Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 2001, 237:145-158.
188. van Amerongen R., Berns A. Knockout mouse models to study Wnt signal transduction. Trends Genet 2006, 22:678-689.
189. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997, 11:3286-3305.
190. Nelson W.J., Nusse R. Convergance of Wnt, β-catenin and cadherin pathways. Science 2004, 303:1483-1487.
191. Bejsovec A. Wnt pathway activation: new relations and locations. Cell 2005, 120:11-14.
192. Hsieh J.C., Kodjabachian L., Rebbert M.L., et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999, 398:431-436.
193. Mao B., Wu W., Li Y., et al. LDL-receptor-related protein 6 is a receptor for dickkopf proteins. Nature 2001, 411:423-424.
194. Zhang T.J., Hoffman B.G., Ruiz de Algara T., Helgason C.D. SAGE reveals expression of Wnt signalling pathway members during mouse prostate development. Gene Expr Patterns 2006, 6:310-324.
195. Mehta V., Abler L.L., Keil K.P., Schmitz C.T., Joshi P.S., Vezina C.M. Atlas of Wnt and R-spondin gene expression in the developing male mouse lower urogenital tract. Dev Dyn 2011, 240:2548-2560.
196. Bierie B., Nozawa M., Renou J.P., et al. Activation of b-catenin in prostate epithelium induces hyperplasia and squamous transdifferentiation. Oncogene 2003, 22:3875-3887.
197. Wu X., Daniels G., Shapiro E., et al. LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol 2011, 25:1018-1026.
198. Simons B.W., Hurley P.J., Huang Z., et al. Wnt signaling though beta-catenin is required for prostate lineage specification. Dev Biol 2012, 371:246-255.
199. Chesire D.R., Ewing C.M., Gage W.R., Isaacs W.B. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002, 21:2679-2694.
200. Joesting M.S., Perrin S., Elenbaas B., et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005, 65:10423-10430.
201. Joesting M.S., Cheever T.R., Volzing K.G., et al. Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. Dev Biol 2008, 317:161-173.
202. Keil K.P., Mehta V., Branam A.M., et al. Wnt inhibitory factor 1 (wif1) is regulated by androgens and enhances androgen-dependent prostate development. Endocrinology 2012, 153:6091-6103.
203. Mann T., Lutwak-Mann C.L. Male reproductive function and semen 1981, Springer-Verlag, New York.
204. Eliasson R. Seminal plasma accessory genital glands and fertility. Male infertility: workup, treatment, and research 1977, 189-204. Grune & Stratton, New York. A.T.K. Crocett, R.L. Urry (Eds.).
205. Bertrand G., Vladesco R. Prostatic zinc concentration. C R Acad Sci 1921, III:176-179.
206. Heathcote J.G., Washington R.J. Analysis of the zinc-binding protein derived from the human benign hypertrophic prostate. J Endocrinol 1973, 58:421-423.
207. Fair W.R., Wehner N. The prostatic antibacterial factor: identity and significance. Prog Clin Biol Res 1976, 6:383-403.
208. Jonsson M., Linse S., Frohm B., Lundwall A., Malm J. Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen. Biochem J 2005, 387:447-453.
209. Zaneveld L.J., Tauber P.F. Contribution of prostatic fluid components to the ejaculate. Prog Clin Biol Res 1981, 75A:265-277.
210. Costello L.C., Franklin R.B. Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production. Prostate 1989, 15:335-342.
211. Costello L.C., Franklin R.B. Effect of prolactin on the prostate. Prostate 1994, 24:162-166.
212. Kavanagh J.P. Isocitric and citric acid in human prostatic and seminal fluid: implications for prostatic metabolism and secretion. Prostate 1994, 24:139-142.
213. Phadke A.M., Samant N.R., Deval S.D. Significance of seminal fructose studies in male infertility. Fertil Steril 1973, 24:894-903.
214. Seligman A.M., Sternberger N.J., Paul B.D., et al. Design of spindle poisons activated specifically by prostatic acid phosphatase (PAP) and new methods for PAP cytochemistry. Cancer Chemother Rep 1975, 59:233-242.
215. Folk J.E., Park M.H., Chung S.I., Schrode J., Lester E.P., Cooper H.L. Polyamines as physiological substrates for transglutaminases. J Biol Chem 1980, 255:3695-3700.
216. Williams-Ashman H.G., Janne J., Coppoc G.L., Geroch M.E., Schenone A. New aspects of polyamine biosynthesis in eukaryotic organisms. Adv Enzyme Regul 1972, 10:225-245.
217. Eliasson R. Studies on prostaglandin; occurrence, formation and biological actions. Acta Physiol Scand Suppl 1959, 46:1-73.
218. White I.G., Darin-Bennett A., Poulos A. Lipids of human semen. Human semen and fertility regulation in men 1976, 144-152. C. V. Mosby, St. Louis. E.S.E. Hafez (Ed.).
219. Poulos A., White I.G. The phospholipid composition of human spermatozoa and seminal plasma. J Reprod Fertil 1973, 35:265-272.
220. Gahankari D.R., Golhar K.B. An evaluation of serum and tissue bound immunoglobulins in prostatic diseases. J Postgrad Med 1993, 39:63-67.
221. Chu T.M., Wang M.C., Kuciel R., Valenzuela L., Murphy G.P. Enzyme markers in human prostatic carcinoma. Cancer Treat Rep 1977, 61:193-200.
222. Lowe F.C., Trauzzi S.J. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 1993, 20:589-595.
223. Watt K.W., Lee P.J., M'Timkulu T., Chan W.P., Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986, 83:3166-3170.
224. Yousef G.M., Diamandis E.P. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin Biochem 2003, 36:443-452.
225. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
226. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990, 143:747-752.
227. Oesterling J.E., Chan D.W., Epstein J.I., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988, 139:766-772.
228. Kyprianou N., Isaacs J. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988, 122:552-562.
229. Huggins C., Stevens R.E., Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209-233.
230. Chung L.W.K., Cunha G.R. Stromal-epithelial interactions: II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 1983, 4:503-511.
231. Russell D.W., Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25-61.
232. Liao S. Cellular receptors and mechanisms of action of steroid hormones. International review of cytology 1975, 87-172. Academic Press, Inc., New York.
233. Wartanabe E., Sudo R., Takahashi M., Hayashi M. Evaluation of poorly water soluble drugs: Validity of the use of additives. Biol Pharm Bull 2000, 23:838-843.
234. Chodak G.W., Kranc D.M., Puy L.A., Takeda H., Johnson K., Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992, 147:798-803.
235. Shabisgh A., Tanji N., D'Agati V., et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999, 140:1920-1926.
236. Matzkin H., Soloway M.S. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992, 21:309-314.
237. Risbridger G.P., Bianco J.J., Ellem S.J., McPherson S.J. Estrogens and prostate cancer. Endocr Relat Cancer 2003, 10:187-191.
238. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-875.
239. Vermeulen A., Kaufman J.M., Goemaere S., van Pottelberg I. Estradiol in elderly men. Aging Male 2002, 5:98-102.
240. Ho S.M. Estrogens and antiestrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004, 91:491-503.
241. King K.J., Nicholson H.D., Assinder S.J. Effect of increasing ratio of estrogen:androgen on proliferation of normal and human prostate stromal and epithelial cells and the malignant cell line LNCaP. Prostate 2006, 66:105-114.
242. Prins G.S., Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73:233-244.
243. Ellem S.J., Risbridger G.P. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 2009, 1155:174-186.
244. Ho S.M., Lee M.T., Lam H.M., Leung Y.K. Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol Metab Clin North Am 2011, 40:591-614. ix.
245. Imamov O., Morani A., Shim G.J., et al. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 2004, 101:9375-9380.
246. Weihua Z., Makela S., Andersson L.C., et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001, 98:6330-6335.
247. Hussain S., Lawrence M.G., Taylor R.A., et al. Estrogen receptor beta activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS One 2012, 7:e40732.
248. Pasquali D., Rossi V., Bellastella G., Bellastella A., Sinisi A.A. Natural and synthetic retinoids in prostate cancer. Curr Pharm Des 2006, 12:1923-1929.
249. Huss J.J., Lai L., Barrios R.J., Hirschi K.K., Greenberg N.M. Retionoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 2004, 61:142-152.
250. Schenk J.M., Riboli E., Chatterjee N., et al. Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2009, 18:1227-1231.
251. Krishnan A.V., Peehl D.M., Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003, 164:205-221.
252. Peehl D.M., Shinghal R., Nonn L., et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 2004, 92:131-141.
253. Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 2012, 523:107-114.
254. Maund S.L., Barclay W.W., Hover L.D., et al. Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 2011, 71:5276-5286.
255. Grayhack J. Pituitary factors influencing growth of the prostate. Biology of the prostate and related tissues 1963, 189-199. U.S. Government Printing Office, Washington. E. Vollmer, G. Kauffmann (Eds.).
256. Liu Y., Costello L.C., Franklin R.B. Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. Metabolism 1996, 45:442-449.
257. Prins G.S. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate. Endocrinology 1987, 120:1457-1464.
258. Assimos D., Smith C., Lee C., Grayhack J.T. Action of prolactin in regressing prostate: independent of action mediated by androgen receptors. Prostate 1984, 5:589-595.
259. Nevalainen M., Valve E., Makela S., Blauer M., Tuohimaa P., Harkonen P. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 1991, 129:612-622.
260. Rouet V., Bogorad R.L., Kayser C., et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 2010, 107:15199-15204.
261. Dagvadorj A., Collins S., Jomain J.B., et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007, 148:3089-3101.
262. Goffin V., Hoang D.T., Bogorad R.L., Nevalainen M.T. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol 2011, 8:597-607.
263. Colao A., Di Somma C., Spiezia S., Filippella M., Pivonello R., Lombardi G. Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. J Clin Endocrinol Metab 2003, 88:88-94.
264. Colao A., Spiezia S., Di Somma C., et al. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. Eur J Endocrinol 2000, 143:61-69.
265. Colao A., Marzullo P., Spiezia S., et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999, 84:1986-1991.
266. Butler A.A., LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001, 142:1685-1688.
267. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 2008, 68:3495-3504.
268. Heidegger I., Ofer P., Doppler W., Rotter V., Klocker H., Massoner P. Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology 2012, 153:4633-4643.
269. Wang Z., Luque R.M., Kineman R.D., et al. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 2008, 149:1366-1376.
270. Anzo M., Cobb L.J., Hwang D.L., et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 2008, 68:3342-3349.
271. Prins G.S. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008, 16:649-653.
272. Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009, 30:293-342.
273. Prins G.S., Calderon E. Environmental contaminants and cancers of the reproductive tract. Environmental impacts on reproductive health and fertility 2010, 194-213. Cambridge University Press, Cambridge, UK. T.J. Woodruff, S. Janssen, L.J. Guillette, L.C. Guidice (Eds.).
274. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8-31. 1.
275. Scardino P.T., Weaver R., Hudson M.A. Early detection of prostate cancer. Hum Pathol 1992, 23:211-222.
276. Jani A.B., Johnstone P.A., Liauw S.L., Master V.A., Brawley O.W. Age and grade trends in prostate cancer (1974-2003): a Surveillance, epidemiology, and end results registry analysis. Am J Clin Oncol 2008, 31:375-378.
277. Altekruse S.F., Kosary C.L., Krapcho M., et al. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission [accessed 10.01.2010]. http://seer.cancer.gov/csr/1975_2007/.
278. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
279. Denis L.J., Carnelro de Moura J.L., Bono A., et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993, 42:119-129. discussion 29-30.
280. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321:419-424.
281. Vogelzang N.J. Enzalutamide-a major advance in the treatment of metastatic prostate cancer. N Engl J Med 2012, 367:1256-1257.
282. Wang X., Kruithof-de Julio M., Economides K., et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 451:495-500.
283. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
284. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008, 4:193-201.
285. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008, 26:2862-2870.
286. Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004, 351:1488-1490.
287. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008, 8:440-448.
288. Knudsen K.E., Kelly W.K. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 2011, 6:483-493.
289. Matuszak E., Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol Metab 2011, 6:469-482.
290. Green S.M., Mostaghel E.A., Nelson P.S. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012, 360:3-13.
291. Ricke W.A., McPherson S.J., Bianco J.J., Cunha G.R., Wang Y., Risbridger G.P. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008, 22:1512-1520.
292. McPherson S.J., Hussain S., Balanathan P., et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 2010, 107:3123-3128.
293. Chan Q.K., Lam H.M., Ng C.F., et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010, 17:1511-1523.
294. Nelles J.L., Hu W.Y., Prins G.S. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 2011, 6:437-451.
295. Kindblom J., Dillner K., Sahlin L., et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003, 144:2269-2278.
296. McPherson S.J., Wang H., Jones M.E., et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001, 142:2458-2467.
297. McGinley J.N., Knott K.K., Thompson H.J. Effect of fixation and epitope retrival on BrdU indices in mammary carcinomas. J Histochem Cytochem 2000, 48:355-362.
298. Correa L.L., Lima G.A., Paiva H.B., et al. Prostate cancer and acromegaly. Arq Bras Endocrinol Metabol 2009, 53:963-968.
299. Reiter E., Kecha O., Hennuy B., et al. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 1995, 136:3338-3345.
300. Pollak M., Beamer W., Zhang J.C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998, 17:383-390.
301. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
302. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
303. Rowlands M.A., Gunnell D., Harris R., Vaktten L.J., Holly J.M., Martin R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer Suppl 2009, 124:2416-2429.
304. Bautista O.M., Kusek J.W., Nyberg L.M., et al. Study design of the medical therapy of prostatic symptoms (MTOPS) trial. Control Clin Trials 2003, 24:224-243.
305. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387-2398.
306. McNeal J. Pathology of benign prostatic hyperplasia. Urol Clin North Am 1990, 17:477-486.
307. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557-563.
308. Kaplan S.A. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008, 102(Suppl. 2):3-7.
309. Nickel J.C. Prostatitis and related conditions, orchitis, and epididymitis. Campbell-walsh urology 2011, 327-356. Elsevier Saunders, Philadelphia. 10th ed. A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters (Eds.).
310. Pontari M.A., Ruggieri M.R. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2004, 172:839-845.